Xxrobxxdo Xxarmxxusaxxnc

Xxrobxxdo Xxarmxxusaxxnc is a pharmaceutical importer and buyer based in the United States, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. The company has established a significant presence in the U.S. pharmaceutical distribution network by importing a diverse range of pharmaceutical products. While specific details about its headquarters and parent company are not publicly disclosed, Xxrobxxdo Xxarmxxusaxxnc plays a pivotal role in ensuring the availability of various pharmaceutical products within the U.S. market.

Xxrobxxdo Xxarmxxusaxxnc's distribution network encompasses multiple warehouse locations across the United States, strategically positioned to facilitate efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are robust, enabling it to manage a substantial volume of imports and coordinate effectively with domestic distribution channels. This extensive network ensures comprehensive geographic coverage, meeting the pharmaceutical needs of various regions within the United States.

In the U.S. pharmaceutical supply chain, Xxrobxxdo Xxarmxxusaxxnc functions primarily as a pharmaceutical importer and buyer. By sourcing finished pharmaceutical formulations from international suppliers, the company acts as an intermediary between foreign manufacturers and the U.S. market. This role is crucial in diversifying the pharmaceutical product offerings available to U.S. consumers and healthcare providers, thereby enhancing market competition and access to a broader range of medications.

Xxrobxxdo Xxarmxxusaxxnc exhibits a high degree of sourcing concentration, with 97.6% of its imports originating from AUROBINDO PHARMA LIMITED, accounting for $13.2 million across 335 shipments. This significant reliance on a single supplier indicates a strategic choice to leverage AUROBINDO's extensive product portfolio and established manufacturing capabilities. However, such concentration also introduces potential risks, including supply chain disruptions due to geopolitical events, regulatory changes, or operational challenges faced by AUROBINDO. The stability of this relationship is evidenced by the consistent volume of shipments over the years, suggesting a strong and reliable partnership.

The resilience of Xxrobxxdo Xxarmxxusaxxnc's supply chain is closely tied to the stability and reliability of AUROBINDO PHARMA LIMITED. The company's limited engagement with other suppliers, such as APL HEALTHCARE LIMITED, which accounts for only 2.4% of imports, indicates a lack of diversified sourcing strategies. This limited diversification may expose Xxrobxxdo Xxarmxxusaxxnc to supply chain vulnerabilities in the event of disruptions affecting AUROBINDO. Additionally, the company's focus on a narrow range of formulations, with 137 unique formulations imported, suggests a specialized product strategy that may limit flexibility in adapting to market changes.

Xxrobxxdo Xxarmxxusaxxnc's sourcing pattern, characterized by a heavy reliance on AUROBINDO PHARMA LIMITED, positions the company to benefit from economies of scale and potentially favorable pricing due to bulk purchasing. However, this strategy also necessitates a comprehensive risk management approach to mitigate potential disruptions. For Indian exporters, understanding Xxrobxxdo Xxarmxxusaxxnc's sourcing preferences presents an opportunity to establish partnerships, particularly in the therapeutic categories where the company imports products. Diversifying the supplier base could enhance supply chain resilience and provide alternative options for Xxrobxxdo Xxarmxxusaxxnc.

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces regulations to ensure that imported drugs meet safety, efficacy, and quality standards. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines the requirements for drug approval, labeling, and manufacturing practices. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drugs and ensuring they meet the necessary standards before entering the U.S. market.

Import licensing requirements for pharmaceutical products in the United States are stringent. Importers must ensure that their products are approved by the FDA and comply with the agency's regulations. Good Manufacturing Practice (GMP) certification is a critical component of this compliance. The FDA recognizes GMP certifications from various international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must verify that their suppliers hold valid GMP certifications from recognized authorities to ensure product quality and safety.

Imported pharmaceutical products must undergo batch testing to confirm their quality, potency, and purity. Stability requirements ensure that drugs maintain their efficacy and safety throughout their shelf life. Labeling must adhere to FDA guidelines, including accurate drug information, usage instructions, and safety warnings. Labeling language requirements mandate that information be presented in English. Serialization mandates require unique identifiers on drug packages to enhance traceability and prevent counterfeit products from entering the supply chain.

Between 2024 and 2026, the FDA implemented several policy changes affecting pharmaceutical imports from India. These changes included enhanced scrutiny of manufacturing facilities, increased inspection frequencies, and stricter enforcement of GMP compliance. The FDA also introduced more rigorous documentation requirements for importers to ensure transparency and traceability in the supply chain. These regulatory adjustments aimed to bolster the safety and efficacy of imported pharmaceutical products and address concerns related to product quality and counterfeit drugs.

Xxrobxxdo Xxarmxxusaxxnc's product strategy focuses on specific therapeutic areas, including Central Nervous System (CNS) & Psychiatric disorders, Advanced Antibiotics, and Cardiovascular conditions. The company's imports in these categories are substantial, with CNS & Psychiatric products accounting for 45.5% of imports, Advanced Antibiotics 32.1%, and Cardiovascular 14.4%. This focus aligns with market demand for treatments in these areas, driven by factors such as the prevalence of mental health conditions, antibiotic resistance, and cardiovascular diseases in the U.S. population.

Xxrobxxdo Xxarmxxusaxxnc's sourcing strategy emphasizes generic drug formulations, particularly in the CNS & Psychiatric, Advanced Antibiotics, and Cardiovascular categories. The company's imports from India, primarily sourced from AUROBINDO PHARMA LIMITED, reflect a preference for established manufacturers with a broad product portfolio. This approach aims to ensure a consistent supply of high-quality generic medications to meet the therapeutic needs of the U.S. market.

Based on its product mix, Xxrobxxdo Xxarmxxusaxxnc serves multiple segments of the U.S. pharmaceutical market. The company's focus on CNS & Psychiatric, Advanced Antibiotics, and Cardiovascular products positions it to supply retail pharmacies, hospitals, and healthcare providers with essential medications. By importing generic formulations, Xxrobxxdo Xxarmxxusaxxnc contributes to the availability of cost-effective treatment options across these therapeutic areas.

There is a realistic opportunity for new Indian suppliers to engage with Xxrobxxdo Xxarmxxusaxxnc, particularly in the therapeutic categories where the company imports products. The company's limited diversification in suppliers suggests potential gaps that new entrants could fill, especially if they can offer competitive pricing, high-quality products, and reliable supply chains. Establishing partnerships with Xxrobxxdo Xxarmxxusaxxnc could provide Indian exporters with access to the U.S. market and enhance their global presence.

Indian exporters seeking to supply Xxrobxxdo Xxarmxxusaxxnc and the U.S. market must adhere to FDA regulations, including obtaining necessary import licenses and ensuring compliance with GMP standards recognized by the FDA. Products must undergo batch testing, meet stability requirements, and have labeling in English that complies with FDA guidelines. Additionally, exporters must implement serialization mandates to facilitate traceability and prevent counterfeit products.

To build a relationship with Xxrobxxdo Xxarmxxusaxxnc, Indian exporters should initiate contact by presenting their product portfolios, emphasizing compliance with FDA regulations, and demonstrating the quality and reliability of their products. Participating in relevant tenders and industry events can enhance visibility and facilitate connections. Developing a comprehensive regulatory filing strategy, including obtaining necessary certifications and approvals, is crucial. Exporters should be prepared for a timeline that includes product evaluation, regulatory review, and potential negotiations, which may span several months.